Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JZP-458 in ALL/LBL Patients Hypersensitive to E. Coli Asparaginase
NCT04145531Phase 3Completed
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Dec 2019
- Primary completion
- Jul 2022
- Modality
- Therapeutic Enzymes
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of crisantaspase recombinant in acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LL), sponsored by Jazz Pharmaceuticals plc. Primary endpoints: Response Rate During the First Course of JZP-458 Administration at 2 weeks and Number of Participants With Any Treatment-emergent Adverse Events. Started Dec 2019; status: completed.
02
Drugs
crisantaspase recombinant
03
Conditions
acute lymphoblastic leukemia (ALL)lymphoblastic lymphoma (LL)
Beyond the preview
Go deeper on NCT04145531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04145531.